Amplia Therapeutics Ltd. (AU:ATX) has released an update.
Amplia Therapeutics Ltd. has successfully completed the allotment of over 67 million shares at $0.115 each, raising $13 million through an institutional placement. This capital raise bolsters Amplia’s financial position as it continues its research and trials, particularly in developing its promising cancer drug, narmafotinib. The company’s strategic focus on FAK inhibitors positions it attractively in the evolving cancer treatment market.
For further insights into AU:ATX stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Will Palantir Stock Crash by 50%? Here’s What Jefferies Expects
- Trump Media Stock Isn’t Worth More Than $3, Says Investor
- ‘Time to Load Up,’ Says Investor About Intel Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
